CardioGenics Holdings Inc · OTC:CGNH
CardioGenics — Investor Presentation (2011)
24 slides from CardioGenics's investor presentation, 2011
Slide 1: SAVASpheres: Novel magnetic beads for optimal light collection
SAVASpheres™ Novel magnetic beads….. for optimal light collection
Slide 2: Background: Magnetic beads (Microspheres)
Background: Magnetic beads (Microspheres) • Magnetic pigment encapsulated in a polymer shell (to isolate from Biologicals) • The polymer shell has functional groups such as Carboxyl, Amino, Epoxy (to facilitate linking biologicals) • Many procedure for polymer encapsulation (patents and know how) •
Slide 3: Background: Applications
Background: Applications • A universal binder to link biological agents (solid phase) • Introduced to the biomedical field 2 decades ago • Today, a significant reagent for the Clinical testing Kits • Used in 90% clinical testing analyzers (immunoassay/DNA) • Used in testing for any disease (Cancer,
Slide 4: Background: Applications
Background: Applications Due to simplicity of use, magnetic particles (MP) are employed in: • Clinical In-Vitro Diagnostic Testing • Immunoassays • DNA testing • Life Sciences Research • Cell & nucleic acid separation • Protein purification • Sample enrichment
Slide 5: Background: Biomedical Market
Background: Biomedical Market • Global IVD market estimated at $42.9 billion in 2007, expected growth to $56 billion by 2012 • Immunoassay testing market is 28% of the IVD testing • Immunoassay analyzers that employ both MP and light reactions represent more than 80% of this market • Estimated MP ma
Slide 6: The In-Vitro-Diagnostics Market
The In-Vitro-Diagnostics Market Source: The Kalorama Report, 2010
Slide 7: Novel Paramagnetic Beads
Novel Paramagnetic Beads \ »-0-6" -” . - 1////,/////1 /)f/
Slide 8: SAVASpheres Silver-Plated Magnetic Beads
SAVASpheres™ Silver-Plated Magnetic Beads
Slide 9: SAVASpheres
SAVASpheres™
Slide 10: SAVASpheres
SAVASpheres™ ar ay = |~ : A ee = & § S//////erssstit
Slide 11: SAVASpheres: Silver-Plated MP
SAVASpheres™: Silver-Plated MP • Silver plated and polymer encapsulated • Manufactured by a simplified process • Beads of various sizes (0.5-50 micron) • Scaled up batch-sizes to commercial lots • Development, supported by NRC through IRAP grants (4 in total)
Slide 12: Color conversion: silver plating
SAVASpheres™ Color conversion: silver plating • A proprietary electroless silver-plating process • Controlled silver thickness, controlled reflectivity-density • No impact on magnetic properties • Chemical/mechanical stability • Post-plating protection (passivation)
Slide 13: Polymer encapsulation (coating)
SAVASpheres™ Polymer encapsulation (coating) • Proprietary polymer encapsulation process • Minimum of three polymer layers: – brightness – functional group density – ion leakage/ion capture • A combination of electrostatic-covalent bonding • A hydrophilic polymer surface - minimizes non- specific bi
Slide 14: Features
SAVASpheres™ Features • Silver-layer with no impact on magnetic moment • 80% magnetic material - quick magnetic response • No deterioration/peeling in salt high solutions • No ion leakage (assessed by enzyme) • Tailored functional surface group (Amino, Carboxyl): – to influence colloidal status – to
Slide 15: Commercialization
Commercialization Current competitive products • All contain dark iron oxide material • Manufactured by magnetic material encapsulation or magnetic pigment insertion in latex particle • Several small Companies (~ 30), three main players • Prices range from $900-$1500/gram of solids • Developed for c
Slide 16: Competitive Advantages
SAVASpheres™ Competitive Advantages • All commercial paramagnetic particles are dark • 90% of Immunoassay Analyzer use light measurements • Maximize light collection by white color conversion • ~ 80% loss of generated light - low testing sensitivity • High magnetic moment, easy manipulation • Hydrop
Slide 17: Up to 7-fold improvement in light signal collection
SAVASpheres™ Compared with beads of all major suppliers, a consistent up to 7 folds improvement in light signal collection with SAVASpheres, • Increased testing sensitivity • Higher test output Posters 41 and 42, Oakridge, AACC, 2007
Slide 18: Potential Markets
Potential Markets • Clinical In-Vitro-Diagnostics testing that employ MP/light – Ten (10) first-tier global IVD test manufacturers – Thirty (30) second-tier IVD test manufacturers – Numerous small regional manufactures Could be adapted to existing/new tests/machinery • Life sciences research applica
Slide 19: Commercial Strategy
Commercial Strategy • A marketing agreement with Merck, signed in 2009 • Two Material Transfer Agreements with 2 other multinationals • Sales Team
Slide 20: Commercial Strategy: Agreement with Merck
Commercial Strategy Agreement with Merck • Executed in 2009, Merck is to receive silver-plated beads • Merck to encapsulate silver beads by their process • After numerous trials, Merck-encapsulated beads did meet the specs • Merck agreed to commercialize SAVASpheres • In October 2011, Merck shipped
Slide 21: Commercial Strategy: Two Material Transfer Agreements
Commercial Strategy The Two Material Transfer Agreements • One in progress (testing) • The other is on-hold
Slide 22: Commercial Strategy: Internal Sales Team
Commercial Strategy Internal Sales Team To Target • Research Laboratories in Universities • Small IVD companies 4 Man team is being set up Internal sales/technical support
Slide 23: Slide 23
Slide 24: Thank you
Thank you LuxSpheres Inc. 6295 Northam Drive, Unit 8 Mississauga, Ontario L4V 1W8 T: 1.905.673.8501 service@luxspheres.com